- Home
- CLGN vs BRNS Comparison
CLGN vs BRNS Comparison
Compare CLGN & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- BRNS
- Stock Information
- Founded
- CLGN 2004
- BRNS 2016
- Country
- CLGN Israel
- BRNS United Kingdom
- Employees
- CLGN N/A
- BRNS N/A
- Industry
- CLGN Industrial Specialties
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- CLGN Health Care
- BRNS Health Care
- Exchange
- CLGN Nasdaq
- BRNS Nasdaq
- Market Cap
- CLGN 44.1M
- BRNS 52.0M
- IPO Year
- CLGN N/A
- BRNS 2021
- Fundamental
- Price
- CLGN $4.19
- BRNS $0.97
- Analyst Decision
- CLGN Strong Buy
- BRNS Strong Buy
- Analyst Count
- CLGN 2
- BRNS 2
- Target Price
- CLGN $12.50
- BRNS $4.00
- AVG Volume (30 Days)
- CLGN 18.1K
- BRNS 31.7K
- Earning Date
- CLGN 11-27-2024
- BRNS 11-06-2024
- Dividend Yield
- CLGN N/A
- BRNS N/A
- EPS Growth
- CLGN N/A
- BRNS N/A
- EPS
- CLGN N/A
- BRNS N/A
- Revenue
- CLGN $689,000.00
- BRNS $14,969,000.00
- Revenue This Year
- CLGN N/A
- BRNS N/A
- Revenue Next Year
- CLGN $670.03
- BRNS N/A
- P/E Ratio
- CLGN N/A
- BRNS N/A
- Revenue Growth
- CLGN N/A
- BRNS 106.21
- 52 Week Low
- CLGN $3.61
- BRNS $0.88
- 52 Week High
- CLGN $6.99
- BRNS $4.16
- Technical
- Relative Strength Index (RSI)
- CLGN 51.28
- BRNS 30.37
- Support Level
- CLGN $3.61
- BRNS $1.28
- Resistance Level
- CLGN $4.39
- BRNS $1.52
- Average True Range (ATR)
- CLGN 0.23
- BRNS 0.13
- MACD
- CLGN 0.09
- BRNS -0.04
- Stochastic Oscillator
- CLGN 59.79
- BRNS 14.09
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.